Background-Diagnostic agreement among pathologists is 84% for ductal carcinoma in situ (DCIS). Studies of interpretive variation according to grade are limited.
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a noninvasive neoplastic breast lesion consisting of cytologically abnormal cells confined to the ducts without extension beyond the basement membrane. Although generally considered a direct precursor to invasive breast carcinoma, DCIS represents a spectrum of abnormality ranging from low-grade lesions with little to no risk for invasive cancer to high-grade lesions with a high likelihood for invasive malignant transformation. 1 Historically, DCIS was detected by palpation and treated with total mastectomy, similar to treatment of invasive carcinoma. The sharp rise in DCIS incidence that occurred in the 1990s was due to detection by screening mammography, which led to discovery of earlier, less aggressive forms of DCIS. However, surgical treatment of DCIS remains remarkably unchanged relative to invasive carcinoma, raising concerns of overtreatment, particularly for lower-grade DCIS.
Although the potential for invasive transformation of DCIS continues to be poorly understood, some immunohistochemical and genetic characteristics are shared between DCIS and invasive cancer. 2 However, validated prognostic genetic markers for DCIS 3, 4 are not yet in common clinical use. Consequently, pathologists in clinical practice often base their diagnoses on assessment of morphologic features, and these diagnoses guide treatment for patients. DCIS grade is determined using several different pathology classification systems 5 --most commonly classified into low-and high-grade, or low-, intermediate-and high-grade categories. Distinguishing DCIS grade along the continuum of breast lesions that range from benign precursors, such as atypical ductal hyperplasia (ADH) to invasive cancer, is critical in determining appropriate treatment and reducing potential overtreatment of indolent cancers. 6 Recent studies indicate discrepancies among pathologists in distinguishing between ADH, DCIS, and invasive cancer. In our previous work in the Breast Pathology Study (B-Path), interpretive agreement was 84% for DCIS, compared to 96% for invasive breast cancer, and 48% for ADH. 7 Although prior studies have noted similar discrepancies for DCIS interpretation 8, 9 , to our knowledge only one has examined pathologist interpretive variation for DCIS by grade, which assessed three DCIS classification systems. 10 The present study estimates diagnostic agreement and quantifies relative over and under interpretation by comparing pathologists' interpretations of low and high-grade DCIS with a reference standard interpretation. We hypothesized that agreement would be higher with high-grade DCIS compared to low-grade DCIS. This study may inform ongoing debates in management of DCIS.
METHODS

Study Population
The B-Path Study enrolled a geographically diverse sample of pathologists from 8 U.S. states (Alaska, Maine, Minnesota, New Hampshire, New Mexico, Oregon, Vermont, Washington). Eligibility included having completed training, and having interpreted breast specimens for at least one year in practice. Pathologists were identified through membership in professional organizations, calls to pathology facilities, internet searches, or their affiliation with the Breast Cancer Surveillance Consortium (BCSC) 11 
Breast Pathology Test Set and Reference Diagnosis
Pathologists were assigned to interpret one of four test sets consisting of 60 breast cases as previously described. 12 The cases were reviewed independently by each pathologist, in random order; no standardized diagnostic definitions were provided. Pathologists recorded their interpretations using a standardized diagnostic form online. 13 Pathologists received up to 20 free Category 1 Continuing Medical Education Credits 14 for participating in this study, which included receiving individualized feedback comparing their categorical diagnoses with both that of their peers and the consensus panel reference diagnoses.
Development of the test cases has been reported in detail elsewhere. 12 Briefly, a stratified sampling design was used to randomly select breast biopsy cases (240 total; 23 invasive carcinoma, 55 high-grade DCIS, 18 low-grade DCIS, 72 atypical hyperplasia (atypia), 72 benign without atypia) from two BCSC screening registries, excluding mastectomy specimens. The registries collect standardized data on women's age, breast density, and biopsy type. One new slide was made for each case. The test sets included a higher proportion of ADH and DCIS cases than would normally be seen in clinical practice to facilitate calculating reasonably stable estimates of agreement for these diagnoses.
Key Definitions
A consensus panel of three expert breast pathologists defined the reference diagnosis for each case. 15 Independent review followed by a modified Delphi approach was used to achieve a consensus diagnosis within diagnostic categories (benign, ductal carcinoma in situ [DCIS] , and invasive carcinoma) for each case. Assessments of nuclear grade and the presence or absence of necrosis (focal or extensive) were recorded for all interpretations of DCIS. We used these two variables to dichotomously classify DCIS into low-and highgrade cohorts for the reference standard and participant pathologist interpretations. Cases with a reference diagnosis of DCIS were divided into "low-grade" and "high-grade" based on the consensus panel's recorded nuclear grade and necrosis score. To maintain sufficient sample size for our statistical analyses, we applied the following definition: any specimen without necrosis and with a low or intermediate nuclear grade was categorized as "low-grade DCIS", and the remainder were classified as "high-grade DCIS." Thus, high-grade DCIS included: specimens with at least focal necrosis and with a low or intermediate nuclear grade; or specimens with high nuclear grade with or without necrosis. This definition is supported by prior evidence from studies showing that 62% of interpretive disagreement in nuclear grade was in distinguishing between low and intermediate grade nuclei, compared to 34% disagreement in distinguishing between intermediate and high-grade nuclei. 16 Thus, establishing a dichotomous classification for DCIS simplified the challenges associated with three tiers of nuclear grade and aligned the classification with potential clinical treatment pathways for DCIS. The consensus panel was not required to achieve consensus on necrosis and nuclear grade during the modified Delphi work, therefore, we used the grade determination from two of three experts if there was not full agreement (majority opinion).
Our analysis thus describes agreement of pathologists using five diagnostic categories for each case: invasive carcinoma (n=23), high-grade DCIS (n=55), low-grade DCIS (n=18), atypical hyperplasia (atypia) (n=72), benign without atypia (n= 72). Over-interpretation was defined as cases classified by the pathologists at a higher diagnostic category relative to the reference; under-interpretation was defined as cases classified lower than the reference diagnosis; concordant cases were those with agreement between the pathologists' and the reference diagnosis.
Statistical Analysis
We summarized counts and frequencies of pathologists by demographic and clinical/practice characteristics. We summarized agreement between the diagnostic categories of the pathologists with that of the reference standard diagnosis. The simple (Cohen's) kappa statistic was used to calculate inter-observer agreement. Within each diagnostic category, we measured the proportion and standard error of pathologists' interpretations that agreed with reference diagnostic categories. We modeled rates of over-and under-interpretation according to diagnostic category using generalized estimating equations (GEE) with an independent correlation structure and robust standard errors to account for correlated response data within a logistic regression model. Estimates and standard errors of Least Square-means were computed and transformed back to the original response scale via the inverse-link function to provide misclassification and agreement rates and their 95% confidence intervals. We used Wald confidence intervals and hypothesis testing to estimate Onega et 
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level of significance for group comparisons. We examined the interpretive variability among low-and high-grade DCIS cases at the case level using descriptive statistics. All analyses were performed using SAS, version 9.4.
RESULTS
Of the 115 pathologists, most were between the ages of 40 and 59 (72%), were not affiliated with an academic center (76%), did not have fellowship training in breast pathology (95%), and were not considered experts in breast pathology by their colleagues (78%). 7 When comparing pathologists' independent interpretations with the reference standard interpretation, pathologists agreed with 46% of the reference-defined low-grade DCIS cases.
Pathologists' interpretations of reference-defined low-grade DCIS cases included the following diagnoses: 16% benign without atypia, 14% atypia, 46% low-grade DCIS, 22% high-grade DCIS, 1% invasive (Table 1 ). In contrast, for high-grade DCIS, 83% of pathologists' interpretations were in agreement (Table 1) . Agreement for low-grade DCIS was similar to atypia (48% and 46%, respectively) ( Figure 1a ). When the reference-defined atypia and low-grade DCIS cases were combined into a single category, agreement within this larger combined categorical grouping was 62%. (Figure 1b) The proportion of reference low-grade DCIS cases over-interpreted was 23% (95% CI 19-28) and the proportion under-interpreted was 30% (95% CI 26-34) ( Table 1) . High-grade DCIS was under-interpreted relative to the reference diagnosis for 14% (95% CI 12-16) of interpretations; only 3% (95% CI 2-4) of interpretations were over-interpreted as invasive carcinoma. Low-grade DCIS cases showed greater variability in interpretation, with a majority of pathologists interpreting many cases in categories other than low-grade DCIS (such as lobular in situ lesions or atypical ductal hyperplasia). An example of a case of lowgrade DCIS with one of the highest diagnostic agreement rates (66% agreement) is shown in Figure 2A -B and an example of a case with low agreement is shown in Figure 2C -D. In contrast, the vast majority of reference high-grade DCIS cases (83%) were interpreted concordantly by most pathologists. Figure 3A -B shows images from a case of consensus high-grade DCIS with 100% agreement and Figure 3C -D shows images from an unusual case with only 7% agreement with the consensus diagnosis of high-grade DCIS.
DISCUSSION
This study provides a novel assessment of the interpretive variability of DCIS by grade in relation to a spectrum of five possible diagnostic categories ranging from benign to invasive breast cancer. Using a national sample of 115 pathologists and a test-set based approach, we found a high level of diagnostic agreement for high-grade DCIS; however, agreement was markedly lower for low-grade DCIS and relatively similar in magnitude to agreement for atypia. Overall, reference low-grade DCIS cases exhibited extensive categorical diagnostic variation by pathologists within individual cases supporting the hypothesis that the inherent histopathological and morphological challenges in the diagnosis of low-grade DCIS are similar to the known challenges in diagnosing atypical ductal hyperplasia. This finding underscores the need for better biomarkers or classification methods to distinguish indolent from aggressive forms of DCIS.
This study expands upon our prior work highlighting challenges in breast pathology interpretation using the B-Path Study test set. 7 We previously reported an overall agreement of 84% for DCIS, which was comparable to agreement for benign without atypia (87%), lower than agreement for invasive carcinoma (96%), and much higher than agreement for atypia (48%). 7 In our previous analysis, 16% of reference DCIS cases were discordant with the reference standard, with 13% under-interpreted as benign or atypia and 3% overinterpreted as invasive. 7 Our findings in the current grade-stratified approach to assessing agreement for DCIS suggest that a large proportion of the discordance stems from challenges associated with inter-observer diagnostic agreement at the lower end of the DCIS spectrum.
Our previous work with this test set demonstrated that atypia (atypical hyperplasia) is often over interpreted as DCIS and this current work demonstrates one third of low-grade DCIS is under-interpreted, emphasizing the challenge pathologists experience categorically segregating atypical hyperplasia from low grade DCIS. Historical and contemporary proposals to address this problem include alternative classification terminology for less aggressive or indolent lesions. 17, 18 Our goal was to objectively evaluate from where on the spectrum of DCIS the majority of discordance stems and not necessarily endorse new classifications; however, we acknowledge that combining atypical hyperplasia and low grade DCIS improved categorical diagnostic agreement to 62%. It should be noted that although pathologists recognize intuitively the challenges and subjectivity of differentiating atypical hyperplasia from low grade DCIS, this issue has undergone limited study using robust methods. Shifting the treatment threshold further up the spectrum of DCIS does not wholly resolve the issue. While our observed concordance for high grade DCIS was 83%, low-grade DCIS was over interpreted as high-grade DCIS for 22% of interpretations. If high grade DCIS is treated more aggressively than low grade DCIS, repercussions persist for patients.
Our prior work also showed that other entities, such as lobular carcinoma in situ (LCIS) can be in the differential diagnosis of low-grade DCIS and this contributes to disagreement in the test set setting. 19 In clinical practice, immunohistochemical stains for e-cadherin can assist differentiating LCIS and DCIS. Further refinements in diagnostic distinction between low and high-grades of DCIS may improve patient treatment outcomes and satisfaction. Ultimately, effective clinical stratification may require the addition of biomarkers such as hormone receptor status, Her2 status, or yet to be discovered biomarkers, in addition to DCIS grade.
Hannemann 20 and others 21 note that making treatment decisions for DCIS based on grade is difficult because of the challenges in assessing histological type and grade. Several studies have shown that high-grade DCIS is more likely to recur and/or recur sooner following local therapy compared to low-grade DCIS. [16] [17] [18] [19] [20] [21] [22] [23] In a natural history study, even low-grade DCIS was associated with subsequent invasive breast cancer in 39% of cases when the follow-up was extended to over four decades. 24 Molecular profiling of DCIS continues to be investigated to identify gene expression profiles that may be strongly correlated with prognosis. However, the morphologic overlap between atypia and low-grade DCIS seems to also exist at the molecular level, such that genetic markers do not yet discriminate well between these two diagnostic categories. 2 As the prognostic value of genetic and morphological features becomes better understood, the inherent challenges of pathologic interpretation of atypia and DCIS may be aided with predictive biomarkers.
Our study suggests that more effort should also be directed at segregating low-grade from high-grade DCIS, particularly when considering implications for clinical management. Wide variation in treatment of DCIS is seen among countries. For example, in a study of 12 countries, 67-90% of women with DCIS had breast conserving surgery, with radiotherapy in 41-100% of those cases. 25 Further, 6-59% received sentinel lymph node biopsy (SNLB) and <1-49% had axillary dissection (ALND), both of which were significantly more likely for larger size and higher grade DCIS lesions. 25 Because access to screening and technical improvements in mammography increased the incidence of DCIS, it follows that reducing screening would decrease incidence; however, opinions are divided and it has been suggested that the problem is overtreatment not overdiagnosis. 27 Different approaches to screening, including risk-based screening, and a willingness to observe more indolent lesions may help address the issues of overdiagnosis and overtreatment. In that regard, a growing recognition of DCIS as a heterogeneous disease, has generated several clinical studies, including the LORD, LORIS, and COMET trials, [26] [27] [28] [29] [30] to test the efficacy of incorporating observation and active monitoring for lower risk DCIS as alternatives to surgical treatment. Thus, diagnostic interpretation of DCIS grade with methods to dichotomously stratify DCIS into treat or observe cohorts is likely to have major implications for management. We will have to wait for outcomes from those clinical trials.
While many studies have examined classification of DCIS by grade based on a variety of characteristics, 5, 10, 25, 28, [31] [32] [33] [34] this study is the largest and the first to use a sample of pathologists from 8 U.S. states to characterize interpretative agreement for low-and highgrade DCIS. This allowed for a more focused evaluation demonstrating the specific end of the spectrum of DCIS that suffers from low diagnostic reproducibility. It should be emphasized that this study only estimates diagnostic variability in a test-set setting and, considering the availability of additional slides, levels, special stains, clinical information and second opinions in clinical practice settings, results of this study are likely an overestimation of diagnostic variability in actual U.S. practice. However, our methods were designed to more closely mimic real-world practice settings than other studies examining diagnostic variability in breast pathology, many of which use highly selected cases with specific areas on slides highlighted for pathologists. Cases in our study were randomly selected in each diagnostic category (rather than being selected as "good for teaching" or "challenging" cases) and the entire slide was available for review. Our study design was an effort to more closely approximate the range of case material that might be seen in typical practice within each of these categories.
Other strengths of this study include use of a standardized pathology interpretation form and the high number of pathologists and test cases. We also were able to estimate rates of overand under-interpretation using a statistical approach that accounted for correlation in individual pathologist's responses. 10 Despite the strengths of this study, we acknowledge limitations inherent to a test-set based study, such as inclusion of only one representative slide per case, no opportunity to employ immunohistochemical markers, no second opinion available, and no additional clinical history information. Further, we defined a broad classification of low-and high-grade DCIS to explore diagnostic variability at the low end of the DCIS spectrum; we recognize that more granular classification systems, which may have their own variation, are used in practice settings. In addition, within our test set of pathology cases, the overall proportion of DCIS was higher than typically found in clinical practice and outcome data are not available.
This study highlights the challenges associated with diagnosing DCIS by focusing on the differences in diagnostic variability of low-grade versus high-grade DCIS. High-grade DCIS is a more reproducible diagnosis with a low likelihood of over interpretation. However, lowgrade DCIS, which accounts for approximately 46% of DCIS lesions, 35 is the major contributor to diagnostic variability within DCIS overall. Future work related to diagnosis and treatment of DCIS needs to clearly distinguish between the forms of this disease that are likely indolent and aggressive. While we await development of validated biomarkers that predict short-term progression of potential precursor lesions, such as ADH and low-grade DCIS to invasive breast cancer, we need to focus on improving pathological interpretation of indolent proliferative disease, accepting inherent challenges in diagnostic reproducibility, and examining less aggressive options for clinical management of low-grade DCIS.
Highlights
• Low-grade DCIS is subject to much greater variability in interpretation than high-grade DCIS A-B) The top two panels show 4x (A) and 20x (B) images from a case of consensus lowgrade DCIS that had one of the highest diagnostic agreement rates (66%). This case has uniform involvement of ducts by a proliferation that has clear cytologic monotony and cribriform architecture with polarized spaces, characteristic of low grade DCIS. It measures just over 2 mm (a size threshold frequently used for a low-grade DCIS diagnosis) and is cut across at the edge of the slide. The majority of participants who did not record a low-grade DCIS diagnosis recorded a highest order diagnosis of ADH (29%) or lobular in situ neoplasia (21%) for the case. C-D) The bottom two panels show 2x (C) and 10x (D) images of a case with only 28% diagnostic agreement with the consensus diagnosis of low-grade DCIS. The majority of participants who did not make this diagnosis recorded a highest order diagnosis of LCIS. The solid growth pattern and low grade monotony present can be seen in either of these diagnostic entities. An E-cadherin stain (which was not available to participants) could help resolve this differential in clinical practice. 
